Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24468Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Makis, A. C. | en |
| dc.contributor.author | Hatzimichael, E. C. | en |
| dc.contributor.author | Stebbing, J. | en |
| dc.date.accessioned | 2015-11-24T19:41:17Z | - |
| dc.date.available | 2015-11-24T19:41:17Z | - |
| dc.identifier.issn | 1462-2416 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24468 | - |
| dc.rights | Default Licence | - |
| dc.subject | Anemia, Sickle Cell/*drug therapy/*genetics/metabolism | en |
| dc.subject | Antisickling Agents/therapeutic use | en |
| dc.subject | Azacitidine/analogs & derivatives/therapeutic use | en |
| dc.subject | Butyrates/therapeutic use | en |
| dc.subject | Drug Resistance | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxyurea/therapeutic use | en |
| dc.subject | Nitric Oxide/therapeutic use | en |
| dc.subject | Pharmacogenetics | en |
| dc.subject | Phenotype | en |
| dc.subject | Poloxamer/therapeutic use | en |
| dc.subject | Polymorphism, Genetic | en |
| dc.subject | Sulfasalazine/therapeutic use | en |
| dc.subject | Toxicogenetics | en |
| dc.title | The genomics of new drugs in sickle cell disease | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.2217/14622416.7.6.909 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16981849 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | The quality of life of patients with sickle cell disease in developed countries has improved significantly over the past two decades. Currently available measures to prevent the painful crises and the complications of the disease include the use of penicillin prophylaxis, antipneumonococcal vaccine, folate administration, chronic red cell transfusions in patients with cerebrovascular disease, iron chelating agents, fetal hemoglobin-enhancing agents, such as hydroxyurea, decitabine and butyrate, drugs that augment the endogenous nitric oxide levels and agents that restore red cell dehydration. Sickle cell patients show a broad phenotypic expression and a great variability in treatment response. Genetic association studies, which attempt to link polymorphisms with certain disease phenotypes and drug response, are taking the first steps in aiding individualized therapy in sickle cell patients in order to enhance efficacy and reduce toxicity. | en |
| heal.journalName | Pharmacogenomics | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
